Tissue Regenix promotes new CEO from within

pharmafile | November 2, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, tissue regenix 

Just over two weeks ago, Tissue Regenix announced that its long-standing CEO, Antony Odell, would be leaving the company. It moved to replace Odell speedily, promoting its non-executive director, Steve Couldwell, to the position of CEO.

Couldwell takes on the position with a fair amount of experience at the upper echelons of the pharmaceutical industry, with his previous position prior to joining Tissue Regenix was as Chief Operating Officer of Sanofi Biosurgery. He began his career in sales, working for Smith & Nephew, the producer of surgical devices and wound care products; in the company, Couldwell rose to the position of Prseident of Orthopaedics, Europe, at the FTSE 100 company.

The incoming CEO commented on his appointment: “Since being appointed to the board in 2013, I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7 billion US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world.”

Tissue Regenix were originally spun out of the University of Leeds in 2006, after commercialising research that has led to products that allow tissue cells to repopulate – allowing for the regenerative medicine to potentially be used to heal wounds, repair heart valves and knee repair.

John Samuel, Chairman, Tissue Regenix: “The Board and I are delighted to welcome Steve as the Group’s new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position.”

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content